(Q37813135)

23 August 2017

1 reference

title

Sclerostin monoclonal antibody therapy with AMG 785: a potential treatment for osteoporosis (English)

1 reference

23 August 2017

0 references

1 reference

1 reference

E Michael Lewiecki

1

1 reference

PubMed ID

21114421

23 August 2017

language of work or name

English

0 references

publication date

29 November 2010

1 reference

Expert Opinion on Biological Therapy

23 August 2017

1 reference

23 August 2017

11

1 reference

23 August 2017

1

1 reference

23 August 2017

117-127

1 reference

Osteoporosis prevention, diagnosis, and therapy

23 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.540565

The worldwide problem of osteoporosis: insights afforded by epidemiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.540565

Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.540565

Candidates for the mechanosensory system in bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.540565

Osteocytes, strain detection, bone modeling and remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.540565

Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.540565

Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.540565

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.540565

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.540565

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.540565

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.540565

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.540565

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.540565

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.540565

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.540565

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.540565

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.540565

Zoledronic acid and clinical fractures and mortality after hip fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.540565

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.540565

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.540565

Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.540565

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.540565

Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.540565

The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.540565

Longitudinal trends in use of bone mass measurement among older americans, 1999-2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.540565

Underdiagnosis of vertebral fractures is a worldwide problem: the IMPACT study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.540565

Osteoporosis is markedly underdiagnosed: a nationwide study from Denmark

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.540565

Undertreatment with anti-osteoporotic drugs after hospitalization for fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.540565

Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.540565

Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.540565

A systematic review of persistence and compliance with bisphosphonates for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.540565

A review of anabolic therapies for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.540565

Bone mineral density in sclerosteosis; affected individuals and gene carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.540565

The natural history of sclerosteosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.540565

Sclerosteosis in a Spanish male: first report in a person of Mediterranean origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.540565

Sclerosteosis: neurogenetic and pathophysiologic analysis of an American kinship.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.540565

Patients with Van Buchem disease, an osteosclerotic genetic disease, have elevated bone formation markers, higher bone density, and greater derived polar moment of inertia than normal

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.540565

A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.540565

Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.540565

Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.540565

Characterization of the Structural Features and Interactions of Sclerostin: MOLECULAR INSIGHT INTO A KEY REGULATOR OF Wnt-MEDIATED BONE FORMATION

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.540565

Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.540565

Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.540565

Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.540565

Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.540565

Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/beta-catenin signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.540565

Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.540565

Mechanisms of anabolic therapies for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.540565

Global gene profiling reveals a downregulation of BMP gene expression in experimental atrophic nonunions compared to standard healing fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.540565

A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.540565

A short treatment with an antibody to sclerostin can inhibit bone loss in an ongoing model of colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.540565

Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.540565

Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.540565

Mechanisms of action and therapeutic potential of strontium in bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.540565

2009 Santa Fe Bone symposium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.540565

Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.540565

The anabolic effects of parathyroid hormone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.540565

Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.540565

10.1517/14712598.2011.540565

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference

PubMed ID

21114421